GENMAB: CLARIFY OVERALL SURVIVAL (OS) WAS SOLE U.S. PRIMARY ENDPOINT IN PHASE 3 EPCORE(®) DLBCL-1 TRIAL AND WAS NOT MET

Reuters · 2d ago

Please log in to view news